Sign In
Buy SGPYY
$42.52
+0.0600 (+0.141%)
At Close: Jun 23, 2026
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Investors Are Encouraged To Assist The Schall Law Firm
11:00am, Sunday, 29'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sa
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Case Against Sage Therapeutics Inc
11:00am, Saturday, 28'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sa
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit – SAGE
05:15pm, Friday, 27'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
Sage Therapeutics, Inc Is Being Sued For Violating Securities Laws And Investors Are Encouraged To Help The Schall Law Firm
11:00am, Friday, 27'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sa
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
10:03am, Friday, 27'th Sep 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options NEW YORK CITY
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain
Shareholders of Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
09:15pm, Thursday, 26'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit – SAGE
07:45pm, Thursday, 26'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 a
